BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7493334)

  • 1. Site-specific modifications of light chain glycosylated antilymphoma (LL2) and anti-carcinoembryonic antigen (hImmu-14-N) antibody divalent f1agments.
    Govindan SV; Goldenberg DM; Griffiths GL; Leung SO; Losman MJ; Hansen HJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5721s-5725s. PubMed ID: 7493334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments.
    Leung S; Losman MJ; Govindan SV; Griffiths GL; Goldenberg DM; Hansen HJ
    J Immunol; 1995 Jun; 154(11):5919-26. PubMed ID: 7751635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.
    Leung SO; Qu Z; Hansen HJ; Shih LB; Wang J; Losman MJ; Goldenberg DM; Sharkey RM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3106s-3117s. PubMed ID: 10541351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
    Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
    Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
    King DJ; Turner A; Farnsworth AP; Adair JR; Owens RJ; Pedley RB; Baldock D; Proudfoot KA; Lawson AD; Beeley NR
    Cancer Res; 1994 Dec; 54(23):6176-85. PubMed ID: 7954464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
    Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of radiolabeled stabilized F(ab')2 fragments of monoclonal antiferritin in nude mouse model.
    Quadri SM; Lai J; Mohammadpour H; Vriesendorp HM; Williams JR
    J Nucl Med; 1993 Dec; 34(12):2152-9. PubMed ID: 8254403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiolabeling of fab and f(ab')2 antibody fragments with 99mTc(I) tricarbonyl core using a new bifunctional tridentate ligand.
    Misri R; Saatchi K; Häfeli UO
    Nucl Med Commun; 2011 Apr; 32(4):324-9. PubMed ID: 21285909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo tumor models for studies of distribution of radiolabelled monoclonal antibodies and fragments.
    Buchegger F; Halpern SE; Sutherland RM; Schreyer M; Mach JP
    Nuklearmedizin; 1986 Dec; 25(6):207-9. PubMed ID: 3808959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab')2 and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection.
    Dadachova E; Bryan RA; Huang X; Ortiz G; Moadel T; Casadevall A
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5629s-5635s. PubMed ID: 17875799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivalent conjugates of poly-gamma-D-glutamic acid from Bacillus licheniformis with antibody F(ab') and glycopeptide ligands.
    Prodhomme EJ; Tutt AL; Glennie MJ; Bugg TD
    Bioconjug Chem; 2003; 14(6):1148-55. PubMed ID: 14624628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiopropyl-agarose as a solid phase reducing agent for chemical modification of IgG and F(ab')2.
    Ferraz N; Leverrier J; Batista-Viera F; Manta C
    Biotechnol Prog; 2008; 24(5):1154-9. PubMed ID: 19194926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments.
    Schott ME; Frazier KA; Pollock DK; Verbanac KM
    Bioconjug Chem; 1993; 4(2):153-65. PubMed ID: 7873647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural human IgG anti-F(ab')2 antibody recognizes a conformational IgG1 hinge epitope.
    Terness P; Kohl I; Hübener G; Battistutta R; Moroder L; Welschof M; Dufter C; Finger M; Hain C; Jung M
    J Immunol; 1995 Jun; 154(12):6446-52. PubMed ID: 7539020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability.
    Rodrigues ML; Snedecor B; Chen C; Wong WL; Garg S; Blank GS; Maneval D; Carter P
    J Immunol; 1993 Dec; 151(12):6954-61. PubMed ID: 7903100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo targeting of malignant melanoma by 125Iodine- and 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen.
    Kang N; Hamilton S; Odili J; Wilson G; Kupsch J
    Clin Cancer Res; 2000 Dec; 6(12):4921-31. PubMed ID: 11156253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo.
    Rogers BE; Franano FN; Duncan JR; Edwards WB; Anderson CJ; Connett JM; Welch MJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5714s-5720s. PubMed ID: 7493333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.